iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

2018 Blood 1,562 citations

Abstract

Abstract The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion–based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.

Keywords

MedicineIbrutinibExpert opinionIntensive care medicineMinimal residual diseaseChronic lymphocytic leukemiaInternal medicineLeukemia

MeSH Terms

Clinical Trials as TopicDisease ManagementGenetic TestingHumansImmunophenotypingKaryotypingLeukemiaLymphocyticChronicB-CellMutationNeoplasm StagingNeoplasmResidualPrognosis

Affiliated Institutions

Related Publications

Publication Info

Year
2018
Type
article
Volume
131
Issue
25
Pages
2745-2760
Citations
1562
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1562
OpenAlex
92
Influential
1333
CrossRef

Cite This

Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. (2018). iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood , 131 (25) , 2745-2760. https://doi.org/10.1182/blood-2017-09-806398

Identifiers

DOI
10.1182/blood-2017-09-806398
PMID
29540348

Data Quality

Data completeness: 86%